Alzheimer’s disease is a neurodegenerative disease that severely affects memory, thinking and behavior. This is known as dementia. Alzheimer’s is responsible for 60-80% of dementia cases in the United States.
In 2018, over 5 million Americans suffered from Alzheimer’s disease. Even though increasing age is a risk factor for Alzheimer’s disease, an estimated 200,000 people with the disease are under the age of 65. Alzheimer’s disease is a serious problem with an estimated 500,000 new cases diagnosed each year.
Alzheimer’s disease gets progressively worse over time. It involves brain degeneration via proteins called beta amyloid plaques deposited in the brain. The beta amyloid gets get in the spaces between nerve cells and Tau proteins form neurofibrillary tangles or twisting tangles inside the cells. This causes a blockage of communication between nerve cells and some believe inhibits the formation of new neurons or neuronal repair.
The symptoms of Alzheimer’s disease:
Difficulty thinking and understanding
Wandering, getting lost
Alzheimer’s disease is treated by numerous medications including Aricept that attempt to control symptoms and slow down the disease. However, there is no cure presently for Alzheimer’s disease.
A 2018 study using a mouse model of Alzheimer’s disease (AD) looked at NAD+ levels and how it affects disease. The study suggested that “compromised cellular bioenergetics and DNA repair contribute to the pathogenesis of Alzheimer’s disease.” The researchers produced a DNA repair-deficient mouse that exacerbates major features of human AD including phosphorylated Tau (pTau) pathologies, synaptic dysfunction, neuronal death, and cognitive impairment.
They reported that the mice have “a reduced cerebral NAD+/NADH ratio indicating impaired cerebral energy metabolism, which is normalized by nicotinamide riboside (NR) treatment.”
Mice that had their NAD levels increased exhibited less DNA damage, less neuroinflammation, and apoptosis of hippocampal neurons and increased activity of SIRT3 in the brain.
The authors concluded that replenishing levels of neuronal NAD+ may provide therapeutic benefits in AD.
In our clinic we deliver NAD+ intravenously which is delivered directly to the brain and body. Although there are no human studies showing the same result for AD, we do know that NAD+ IV therapy decreases inflammation, increases mental clarity and improves mitochondrial dysfunction. Since our NAD+ IV therapy is a natural substance with excellent safety, we are offering to early onset Alzheimer’s with the understanding that it is of possible therapeutic benefit.